During the last three months, 7 analysts shared their evaluations of Kymera Therapeutics (NASDAQ:KYMR), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.86, a high estimate of $65.00, and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 26.58% increase from the previous average price target of $38.60.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Kymera Therapeutics among financial experts...
Login or create a forever free account to read this news
Sign up/Log in